Start your Trading & Investing Journey with us

Join our channel for Daily Free Trades with Live analysis on Youtube, Trade Setup with Important Levels, and Important Stock Market Updates

Park Medi World IPO Review - Issue Date, Price, GMP, Subscription, Allotment, Lot Size, and Details

Park Medi World Limited is a multi-specialty hospital chain operating a network of 15 hospitals with ~3,500+ beds across South India. The company earns revenue through inpatient and outpatient services, critical care, diagnostics, and day-care procedures. Its key medical offerings include cardiology, oncology, mother & child care, renal sciences, and emergency services, serving patients through a hub-and-spoke healthcare model.

Park Medi World, an Book Built Issue, amounting to â‚¹920.00 Crore,consisting an fresh issue of 4.75 crore shares worth ₹770.00 crores and offer for sale of 0.93 crore shares totaling to ₹150.00 crores. The subscription period for the Park Medi World IPO opens on December 10, 2025, and closes on December 12, 2025. The allotment is expected to be finalized on or about Monday, December 15, 2025., and the shares will be listed on the BSE & NSE with a tentative listing date set on or about Wednesday, December 17, 2025.

The Share Price Band of Park Medi World IPO is set at â‚¹154 to ₹162 per equity share. The Market Capitalisation of the Park Medi World at IPO price of ₹162 per equity share will be â‚¹6997.28 Crores. The lot size of the IPO is 92 shares. Retail investors are required to invest a minimum of  â‚¹ 14,904, 1 lots ( 92 shares), while the minimum investment for High-Net-Worth Individuals (HNIs) is 14 lots ( 1288 shares), amounting to â‚¹ 208,656.

Nuvama Wealth Management Limited, CLSA India Private Limited, DAM Capital Advisors Limited, and Intensive Fiscal Services Private Limited,are the book running lead manager of the Park Medi World Ltd. while Kfin Technologies Limited is the registrar for the issue.

Park Medi World Limited IPO GMP Today
The Grey Market Premium of Park Medi World IPO is expected to be â‚¹0 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.

Park Medi World Limited IPO Live Subscription Status Today: Real-Time Update
As of 10:30 AM on 11 December, 2025, the Park Medi World IPO live subscription status shows that the IPO subscribed 0.13 times on its Second Day of subscription period. Check the Park Medi World IPO Live Subscription Status Today at BSE.

Park Medi World Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Park Medi World IPO allotment date is 15 December 2025, Monday, Park Medi World IPO Allotment will be out on 15 December 2025, Monday.and will be live on Registrar Website from the allotment date.
Check Kfin Technologies Limited IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Park Medi World IPO from the dropdown list of IPOs
- Enter your application number, PAN, or DP Client ID
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.

Objectives of Park Medi World Limited IPO
Park Medi World to utilise the Net Proceeds towards the following objects:
1. ₹3,800.00 Million is required for Repayment/ prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries
2. ₹605.00 Million is required for Funding capital expenditure for development of new hospital by our Subsidiary Park Medicity (NCR)
3. ₹274.59 Million is required for Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens and Ratangiri
4. General Corporate Expenses

Refer to Park Medi World Limited RHP for more details about the Company.

Park Medi World Limited Day Wise IPO GMP Trend
GMP Date Issue Price Expected Listing Price GMP Last Updated
December 06, 2025 N/A N/A ₹0(0.0%) 06 December 2025; 11:16 AM
Park Medi World IPO Details
Market Capitalization ₹6997.28 Cr.
IPO Date December 10, 2025 to December 12, 2025
Listing Date December 17, 2025
Face Value ₹2 Per Share
Price Band ₹154 to ₹162 per share
Issue Price ₹162 per share
Employee Discount NA
Lot Size 92 Equity Shares
Total Issue Size 5,67,90,123 Equity Shares (aggregating to ₹920.00 Cr)
Fresh Issue 4,75,30,864 Equity Shares (aggregating to ₹770.00 Cr)
Offer for Sale 92,59,259 Equity Shares (aggregating to ₹150.00 Cr)
Issue Type Book Built Issue
Listing At BSE & NSE
Share holding pre issue 38,44,00,000
Share holding post issue 43,19,30,864
Rating Avoid
Park Medi World IPO Anchor Investors Details
Bid Date December 09, 2025
Shares Offered 1,70,37,036
Anchor Portion Size (In Cr.) 276.00
Anchor lock-in period end date for 50% shares (30 Days) January 14, 2026
Anchor lock-in period end date for remaining shares (90 Days) March 15, 2026
Park Medi World IPO Timeline (Tentative Schedule)
IPO Open Date Wed, Dec 10, 2025
IPO Close Date Fri, Dec 12, 2025
Basis of Allotment Mon, Dec 15, 2025
Initiation of Refunds Tue, Dec 16, 2025
Credit of Shares to Demat Tue, Dec 16, 2025
Listing Date Wed, Dec 17, 2025
Cut-off time for UPI mandate confirmation 5 PM on Fri, Dec 12, 2025
Park Medi World IPO Reservation
Investor Category Shares Offered Reservation %
QIB Portion 28,395,062 Not less than 50% of the Net Offer
Non-Institutional Investor Portion 8,518,519 Not more than 15% of the Net Issue
Retail Shares Offered 19,876,543 Not more than 35% of the Net Offer
Park Medi World IPO Promoter Holding
Share Holding Pre Issue 95.55%
Share Holding Post Issue 85.04%
Park Medi World IPO Lot Size
Application Lots Shares Amount
Retail (Min) 1 92 ₹14,904
Retail (Max) 13 1,196 ₹193,752
S-HNI (Min) 14 1,288 ₹208,656
S-HNI (Max) 67 6,164 ₹998,568
B-HNI (Min) 68 6,256 ₹1,013,472
Park Medi World IPO Subscription Status
Investor Category Shares Offered Shares Bid For No of Times Subscribed Last Upadeted
Qualified Institutional Buyers (QIB) 1,19,48,052 2,74,23,820 2.30x 12 December 2025; 06:46 PM
Non Institutional Investors(NIIS) 89,61,039 2,34,25,132 2.61x 12 December 2025; 06:46 PM
Retail Individual Investors (RIIs) 2,09,09,091 1,57,73,124 0.75x 12 December 2025; 06:46 PM
Total 4,18,18,182 6,66,22,076 1.59x 12 December 2025; 06:47 PM
About Park Medi World Limited

Park Medi World Limited is a multi-specialty hospital chain operating a network of 15 hospitals with ~3,500+ beds across South India. The company earns revenue through inpatient and outpatient services, critical care, diagnostics, and day-care procedures. Its key medical offerings include cardiology, oncology, mother & child care, renal sciences, and emergency services, serving patients through a hub-and-spoke healthcare model.

Key Clients & Major Facilities
The company primarily serves retail patients, corporate employees under tie-ups, government scheme beneficiaries, and insurance-backed patients. Its major hospitals are located in Chennai, Coimbatore, Madurai, Tirunelveli, Vijayawada, Hyderabad, and Bengaluru, equipped with ICUs, operation theatres, and advanced diagnostic centers. Flagship facilities like Park Hospitals Chennai and Coimbatore act as high-acuity tertiary-care centers.

Product/Service Portfolio & Order Execution
Park Medi World’s portfolio includes surgical treatments, emergency care, advanced diagnostics, organ-related specialties, and critical-care services. These services sit at the core of the patient life cycle—from preventive consultations to surgery and recovery—ensuring recurring demand. Revenue visibility remains strong due to consistent patient inflow across specialties, while capacity expansion and improved occupancy across hospitals support operational execution and long-term service scalability.

Mergers, Capex & Expansion Plans
The company is focused on expanding bed capacity across regions while upgrading existing hospitals with advanced medical technologies. Planned capex prioritizes new specialties, equipment modernization, and selective acquisitions to grow the hospital network. The strategy aims to enhance its geographical footprint, improve patient mix, and strengthen clinical infrastructure for sustained long-term growth.

Employees & Banker
As of Sep 30, 2025, the company had 1566 employees. The Banker to the Company is 
Axis Bank Limited.

MANAGEMENT & THEIR GROWTH VISION

Promoters and management aim to position Park Medi World as a leading integrated healthcare provider across South India, targeting higher occupancy, improved case-mix, and expanded tertiary-care offerings. Their long-term vision includes expanding hospital capacity, scaling specialty treatments, and adopting technology-driven healthcare delivery. Funding for future capex is expected to come from IPO proceeds, internal accruals, and strategic debt refinancing to maintain a balanced capital structure. The management emphasizes disciplined expansion to deliver sustainable double-digit growth in the coming years.

INDUSTRY OVERVIEW

India’s healthcare industry is one of the fastest-growing globally, driven by rising lifestyle diseases, higher insurance penetration, and expanding medical infrastructure. The Indian hospital industry was valued at over USD 95–100 billion, expected to grow at ~10–12% CAGR, supported by demand for tertiary and quaternary care. The global hospital industry exceeds USD 2 trillion, growing at 6–7% CAGR. Market leaders in India include Apollo Hospitals, Fortis Healthcare, Narayana Health, and Aster DM Healthcare. The long-term outlook remains strong with increasing patient loads, technological advancements, and public–private healthcare initiatives.

KEY RISK FACTORS

  1. High Regional Concentration
    A significant portion of hospital capacity is located in South India, which exposes the company to region-specific economic, regulatory, and competitive risks that may impact patient inflow and revenue stability.
  2. Dependence on Healthcare Professionals
    Recruitment and retention of qualified doctors, nurses, and technicians are critical. Shortages or departures of key specialists can affect service quality, hospital occupancy, and revenue performance.
  3. Regulatory and Compliance Risks
    Healthcare providers must comply with strict medical, environmental, safety, and pricing regulations. Any unfavorable changes may increase costs, restrict pricing flexibility, or delay expansion projects.
  4. High Competition in Hospital Sector
    The company competes with established chains like Apollo, Fortis, and Aster. Competitive pricing, superior infrastructure, or better specialists at rival hospitals may pressure margins and occupancy rates.
  5. Capex-Intensive Business Model
    Hospital expansion requires substantial investments in equipment, buildings, and technology. Any delay in capex execution or inability to optimally utilize new beds can impact returns and financial performance.
  6. Dependence on Insurance & Government Schemes
    A growing share of patients come through insurance and government reimbursements. Pricing caps or delayed reimbursements may affect cash flows and profitability.
  7. Operational Risks and Medical Liabilities
    Hospitals face medical negligence claims, equipment failures, and operational incidents. Such events may result in financial penalties, legal liabilities, and reputational damage.

KEY STRENGTHS & OPPORTUNITIES

  1. Strong Regional Presence
    With ~3,500+ beds across major South Indian cities, the company benefits from deep regional penetration and strong brand recognition, enabling consistent demand across specialties.
  2. Diverse Multispecialty Portfolio
    The company provides comprehensive care spanning cardiology, oncology, renal sciences, mother & child care, and trauma. This diversified mix ensures broad patient coverage and reduces dependence on any single segment.
  3. Hub-and-Spoke Scalable Model
    Flagship tertiary-care hospitals supported by secondary centers create an efficient patient referral system. This model boosts occupancy, optimizes resources, and supports expansion into new catchment areas.
  4. Favorable Industry Tailwinds
    India’s strong healthcare demand, rising insurance penetration, and increasing chronic disease burden offer long-term opportunities for expansion, higher patient footfall, and premium specialty services.
  5. Capacity Expansion Opportunity
    Plans to add beds and upgrade equipment create strong growth visibility. Modernization and specialty additions can improve case-mix, leading to higher average revenue per occupied bed (ARPOB).
  6. Operational Efficiency & Scalability
    A disciplined approach to cost control, improved bed utilization, and structured clinical processes supports margin expansion and enables the platform to scale effectively across new geographies.

Park Medi World Limited Financial Information (Restated Consolidated)

Amount in (₹ in Million)

Period Ended Sep 30, 2025 Mar 31, 2025 Mar 31, 2024 Mar 31, 2023
Reserve of Surplus 11,239.00 9,927.03 8,059.15 6,096.81
Total Assets 23,209.29 21,337.03 19,120.99 15,928.23
Total Borrowings 6,356.55 6,224.37 6,326.52 5,572.40
Fixed Assets 7,559.53 7,643.25 7,071.24 4,404.98
Cash 533.85 1,030.04 766.26 1,000.46
Cash flow from operating activities 454.92 1,911.51 3,614.35 1,950.29
Cash flows from investing activities -739.76 -911.67 -2,545.52 -1,796.31
Cash flow from financing activities -211.35 -736.06 -1,303.02 15.14
Net Borrowing 5,822.70 5,194.33 5,560.26 4,571.94
Revenue 8,233.94 14,259.74 12,630.84 12,721.77
EBITDA 2,171.36 3,721.73 3,103.01 3,903.41
PAT 1,391.43 2,132.15 1,520.07 2,281.86
PAT Margin 16.90% 14.95% 12.03% 17.94%
EPS 3.62 5.55 3.95 5.94

Note 1:- RoE, ROCE & RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 2:- Pre EPS and Post EPS calculation in KPI is based (Profit/Loss for the Year) on 31st Mar, 2025 Data, given in RHP.
Note 3:- RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Note 4:- Price to Book Value calculation in KPI is based on Cap Price Post Issue Data, given in FINANCIAL EXPRESS.

Key Performance Indicator
KPI Values
EPS Pre IPO (Rs.) 5.55
EPS Post IPO (Rs.) 4.94
Adjusted 12M EPS Post IPO (Rs.) 6.44
P/E Pre IPO 29.19
P/E Post IPO 32.82
Adjusted 12M P/E Post IPO 25.14
ROE 20.68%
ROCE 17.47%
P/BV 6.09
Debt/Equity 0.61
RoNW 20.08%
EBITDA Margin 26.71%
PAT Margin 14.95%
Park Medi World Limited IPO Peer Comparison
Company Name EPS P/E (x) ROE ROCE P/BV Debt/Equity RoNW (%)
Park Medi World 4.94 32.82 20.68% 17.47% 6.09 0.61 20.08%
Apollo Hospitals Enterprise 100.56 73.43 18.4 % 16.6 % 11.0 0.88 17.63%
Fortis Healthcare 10.26 90.42 10.1 % 12.0 % 6.89 0.34 8.69%
Narayana Hrudalaya 38.90 50.10 24.2 % 20.8 % 9.48 0.58 21.80%
Max Healthcare Institute 11.07 101.54 12.7 % 14.9 % 10.5 0.33 11.47%
Krishna Institute of Medical Sciences 9.61 69.53 18.5 % 15.0 % 11.6 1.40 17.89%
Global Health 17.92 66.41 16.5 % 19.7 % 8.35 0.25 14.27%
Jupiter Lifeline Hospitals 29.47 48.59 15.0 % 18.0 % 6.35 0.28 14.27%
Yatharth Hospital & Trauma Care Services 14.72 52.85 10.4 % 14.0 % 3.93 0.02 8.15%
Park Medi World Limited Contact Details

Park Medi World Limited
Phone: + 91 124 696 0000
Email: company.secretary@parkhos pital.in
Website: http://www.parkhospital.in

Park Medi World IPO Registrar and Lead Manager(s)

Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: parkmedi.ipo@kfintech.com
Websitehttps://ipostatus.kfintech.com/

  1. Nuvama Wealth Management Ltd.
  2. CLSA India Pvt.Ltd. 
  3. Dam Capital Advisors Ltd. 
  4. Intensive Fiscal Services Pvt.Ltd.

Park Medi World IPO Review

Park Medi World Limited is a multi-specialty hospital chain operating a network of 15 hospitals with ~3,500+ beds across South India. The company earns revenue through inpatient and outpatient services, critical care, diagnostics, and day-care procedures. Its key medical offerings include cardiology, oncology, mother & child care, renal sciences, and emergency services, serving patients through a hub-and-spoke healthcare model.
The Company is led by Promoter, i.e., DR. AJIT GUPTA AND DR. ANKIT GUPTA

The Revenues from operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 8,233.94 Million, ₹ 14,259.74 Million, â‚¹ 12,630.84 Million, and ₹ 12,721.77 Million, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 2,171.36 Million, ₹ 3,721.73 Million, ₹ 3,103.01 Million, and ₹


Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. We also use Artificial Intelligence (AI) tools to enhance the efficiency and quality of our research services, including data retrieval, analysis, and report summarization. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit Legal our website abhayvarn.com

About the Author
CA Abhay Kumar (Also known as  CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.

Services

Equity Investment with CA Abhay

Equity Trading with CA Abhay

Option Trading with CA Abhay

Stock Market Masterclass

© 2022 CA Abhay Varn. All Rights Reserved Abhayvarn.com